Osteonecrosis of the Jaw during Sorafenib Therapy for Hepatocellular Carcinoma

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Tumori

• Publication date

  2016-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.5301/tj.5000504PMID 27079903
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multicenter Study and Review of the Literature.

  2015cited by this paper
• Sorafenib in Advanced Hepatocellular Carcinoma-Clinical Experience

  2013cited by this paper
• Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw.

  2012cited by this paper
• Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases

  2012cited by this paper
• Sorafenib-induced bilateral osteonecrosis of femoral heads.

  2010cited by this paper
• Osteonecrosis of the jaws induced by drugs other than bisphosphonates - a call to update terminology in light of new data.

  2010cited by this paper
• Toxicity of sorafenib: clinical and molecular aspects

  2010cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008influential reference

• A literature review and update on medications related to osteonecrosis of the jaw independent of bisphosphonates and denosumab

  2025cites this paper
• Bone Effects of Anti-Cancer Treatments in 2024

  2025cites this paper
• Medication‐Related Osteonecrosis of the Jaw Caused by Drugs With Antiangiogenic Effects—What Should the Clinician Be Aware of and What Course of Treatment Can Be Applied? A Systematic Review of Case Series and Case Reports

  2024cites this paper
• Sorafenib-Associated Bilateral Osteonecrosis of the Femoral Head.

  2024cites this paper
• Exploring the Impact of Novel Anti-Cancer Therapies on Jaw Osteonecrosis and Other Bones: A Comprehensive Review

  2024cites this paper
• Osteonecrosis of the Jaws: An Update and Review of Literature

  2023cites this paper
• The impact of sex steroids on osteonecrosis of the jaw

  2022cites this paper
• Osteonecrosis of the Jaws in Patients with Hereditary Thrombophilia/Hypofibrinolysis—From Pathophysiology to Therapeutic Implications

  2022cites this paper
• Adverse events associated with bone-directed therapies in patients with cancer.

  2021cites this paper
• Management of Patients under Treatment with Monoclonal Antibodies and New Biological Therapies

  2021cites this paper
• Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates

  2021cites this paper
• Medication-Related Osteonecrosis of the Jaw Spontaneously Occurred in a Patient with Chronic Myelogenous Leukemia Only by Imatinib: A Report of a Rare Case

  2021cites this paper
• Medication-Related Osteonecrosis of the Jaws and CDK4/6 Inhibitors: A Recent Association

  2020cites this paper
• [Current evidence-based approaches and international guidelines in primary and secondary prevention strategies of medication-related osteonecrosis of the jaws].

  2020cites this paper
• Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma

  2020cites this paper
• Osteonecrosis of the jaws associated with protein kinase inhibitors: a systematic review

  2020cites this paper
• Osteonecrosis of the jaw associated with imatinib therapy in myeloproliferative neoplasm: a rare case report.

  2020cites this paper
• Systematic review of medication related osteonecrosis of the jaw (MRONJ) in patients undergoing only antiangiogenic drug therapy: surgery or conservative therapy?

  2020cites this paper
• Aktualitások a gyógyszer okozta állcsontelhalás primer és szekunder prevenciójának stratégiájában az evidenciák és a nemzetközi ajánlások tükrében Current evidence-based approaches and international guidelines in primary and secondary prevention strategies of medication-related osteonecrosis of the

  2020cites this paper
• Nationwide Multicentric Retrospective and Prospective Epidemiologic Survey of Bisphosphonate-related Osteonecrosis of the Jaws

  2020cites this paper
• Aktualitások a gyógyszer okozta állcsontelhalás primer és szekunder prevenciójának stratégiájában az evidenciák és a nemzetközi ajánlások tükrében Current evidence-based approaches and international guidelines in primary and secondary prevention strategies of medication-related osteonecrosis of the

  2020cites this paper
• Aktualitások a gyógyszer okozta állcsontelhalás primer és szekunder prevenciójának stratégiájában az evidenciák és a nemzetközi ajánlások tükrében Current evidence-based approaches and international guidelines in primary and secondary prevention strategies of medication-related osteonecrosis of the

  2020cites this paper
• Aktualitások a gyógyszer okozta állcsontelhalás primer és szekunder prevenciójának stratégiájában az evidenciák és a nemzetközi ajánlások tükrében Current evidence-based approaches and international guidelines in primary and secondary prevention strategies of medication-related osteonecrosis of the

  2020cites this paper
• Osteonecrosis of the External Auditory Canal Associated With Oral Sorafenib Therapy: Sorafenib and Temporal Bone Osteonecrosis.

  2019cites this paper
• Risk profile for antiangiogenic agent-related osteonecrosis of the jaws

  2019influential citation
• Osteonecrosis of the Jaws in Patients Receiving Anti-Angiogenic Drugs and Chemotherapeutics: Literature Review and Case Reports

  2019cites this paper
• Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab-a review.

  2019cites this paper
• Review and update on drugs related to the development of osteonecrosis of the jaw

  2019cites this paper
• Osteonecrosis of the jaw in the era of targeted therapy and immunotherapy in oncology

  2019cites this paper
• Osteonecrosis of the Jaw during Lenvatinib Therapy: A Case Report Based on Surgical Management

  2019cites this paper
• Risk factors for medication-related osteonecrosis of the jaws: a case-control study in Queensland, Australia

  2019cites this paper
• Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review

  2018cites this paper
• Current Understanding of the Pathophysiology of Osteonecrosis of the Jaw

  2018cites this paper
• [Osteoprotective therapy with bisphosphonates or denosumab in patients with multiple myeloma: benefit and risks].

  2018cites this paper
• Osteonecrosis of the Jaw Associated with Antiangiogenics in Antiresorptive-Naïve Patient: A Comprehensive Review of the Literature

  2018cites this paper
• Osteonecrosis of the Jaw and Angiogenesis inhibitors: A Revival of a Rare but Serous Side Effect.

  2017cites this paper
• A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer

  2017cites this paper
• Otorhinolaryngological Toxicities of New Drugs in Oncology

  2017cites this paper